Home Blog Page 798

“It Survived 40,000 Feet, Drier Than the Sahara”–The Ultimate K-Beauty Barrier Cream Just Landed on Amazon

By
Advertorial Desk
-

The evolution of a 10-year R&D heritage that previously swept top US luxury department stores. Meet Dr.BRID C, the next-generation biotech skincare line launching on Amazon—all under $25.

NEW YORK and SEOUL, South Korea, March 23, 2026 /PRNewswire/ — Altitude 40,000 feet. Humidity below 20%. If you’ve ever looked in the mirror after a long-haul flight to find your skin rough, red, and completely parched, this new beauty brand’s origin story will instantly resonate with you.

Dr.BRID C, the next-generation biotech skincare line launching on Amazon
Dr.BRID C, the next-generation biotech skincare line launching on Amazon

Born out of the desperate need for VIPs and beauty professionals to protect their skin in harsh, Sahara-like cabin environments, the next-generation biotech K-beauty brand Dr.BRID C has officially launched on US Amazon.

The ‘Paradox of Beauty’: How We’re Destroying Our Own Skin
Even on the ground, our skin is under daily attack as if it were 40,000 feet in the air. Air conditioning, pollution, and ironically, our daily beauty routines—heavy makeup, harsh double-cleansing, and chemical exfoliation—are slowly stripping away our skin barrier.

To break this vicious cycle, Dr.BRID C goes beyond temporary fixes with a clear and uncompromising philosophy: “Defense Before Beauty.”

Luxury Skincare Science That Awakens ‘C-Peptide’
Dr.BRID C’s barrier-repairing prowess is rooted in a 10-year R&D heritage that previously dominated luxury US department stores like Barneys New York.

Rejecting conventional moisturizers that just suffocate the skin with heavy oils, their scientists developed a proprietary patented technology: PEPTIBRID®. This technology encapsulates a powerful collagen-signaling peptide in soothing zinc oxide, delivering it safely and deeply into the skin. In cell tests, this resulted in a massive 175.3% surge in ‘C-peptide,’ a key biomarker for new collagen synthesis.

“When trying to create a cream that could help skin survive a 14-hour flight, we realized surface hydration simply wasn’t enough,” says the Lead Researcher at Dr.BRID C. “Dr.BRID C helps build the fundamental strength skin needs to breathe and defend itself in any extreme environment.”

“Balanced and Springy”—Real Customers Prove the Barrier Miracle
Dr.BRID C focuses on rebuilding the skin’s core rather than just offering a temporary band-aid. And real customer reviews are already proving the miracle.

An Amazon reviewer who suffered from a compromised oil-water balance and tightness praised the texture and moisture retention: “This cream moisturizer is smooth and makes the skin feel soft after overnight wear without lingering filminess or discomfort. Skin does not feel greasy or oily but balanced and springy.”

Furthermore, testers who experienced extreme inner dryness from frequent travel and UV exposure testified to the overwhelming difference: “I have sensitive skin, so after traveling, UV exposure makes my skin reactive and dry… This feels like I’ve finally found the right cream. It spreads smoothly and absorbs quickly without leaving residue. It addresses inner dryness beautifully.”

The #40,000ft Cream Lineup: A Customized Barrier Trio (All Under $25)
Driven by the “Defense Before Beauty” philosophy, the launch centers around three targeted #40,000ft Creams designed for specific skin conditions.

  • #40,000ft Barrier Defense Basic Cream ($19.99): The absolute hero of the lineup. Formulated with an optimal 12ppm of PEPTIBRID®, this cream becomes your new daily shield if your oil-water balance has collapsed. It absorbs instantly without any greasiness, creating the perfect velvet canvas for your makeup to grip onto.
  • #40,000ft Hydro Relief Cream ($21.99): A cooling gel-cream packed with a high concentration of 21ppm PEPTIBRID® for sensitized, dehydrated skin. Just one use blocks Trans-Epidermal Water Loss (TEWL) by 30.81%, delivering an instant hit of deep hydration.
  • #40,000ft Intensive Moisture Basic Cream ($21.99): The ultimate age-defying density care. Boasting 22ppm of PEPTIBRID®—the highest concentration in the lineup—it goes beyond barrier support to visibly improve signs of aging like enlarged pores, rough texture, and eye wrinkles over 8 weeks.

Rounding out the collection is a synergistic, clean-formula lineup—including a pH-balancing toner and a 100-hour moisture-locking serum—all priced under $25. If you’re ready to experience cutting-edge barrier defense that survives even the harshest conditions, Dr.BRID C is available now on Amazon(https://www.amazon.com/drbridc?maas=maas_adg_EE29DA495FDC3C85E3F4533006833714_afap_abs&ref_=aa_maas&tag=maas).

 

WuXi XDC Delivers Exceptional Performance in 2025, Reinforcing Global Leadership in Bioconjugate CRDMO

By
Advertorial Desk
-
  • Revenue increased by 46.7% YoY to RMB 5,944 million
  • Gross profit surged by 72.5% YoY to RMB 2,139 million, with its margin of 36.0%, a 5.4 percentage points increase compared to 2024
  • Adjusted net profit increased by 69.9% YoY to RMB 1,559 million, with its margin of 26.2%, a 3.6 percentage points increase compared to 2024(excluding net interest income and exchange impact)
  • The total global customer base expanded to over 640 companies, and 14 out of the TOP 20 global pharmaceutical companies have partnered with us
  • The total number of iCMC projects reached to 252, with 70 newly signed iCMC projects
  • The robust PPQ pipeline: Secured 18 PPQ projects with 10 new PPQ projects added in 2025
  • The total backlog grew to US$1.49 billion, representing a strong 50.3% YoY growth
  • Winner of “Best CDMO” and “Best CRO” Awards: Three consecutive “Best CDMO” Awards from 2023 to 2025 at World ADC Awards, and “Best CRO” Awards at 2025 World ADC Awards

SHANGHAI, March 23, 2026 /PRNewswire/ — WuXi XDC Cayman Inc. (the “WuXi XDC” or the “Group”, stock code: 2268.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) focused on the bioconjugate market, is pleased to announce its annual results for 2025 (the “Reporting Period”).

Management Discussion on 2025 Annual Results and Recent Events (Jan to March 2026)

  • Rapid Growth – As a leading player in the thriving, innovative global bioconjugates industry, the Group has maintained its rapid business growth by providing world-class bioconjugates CRDMO integrated services and empowering its global partners to accelerate and transform ADC and broader bioconjugate development.
  • Strategic M&A – Beyond strong operational results, we advanced two strategic M&A initiatives that elevated our extensive capabilities and expanded our global footprint, enabling us to better serve the global customers. (including the Suzhou site from the acquisition of BioDlink, and the Hefei site acquisition)
  • Technology Engine – Breakthrough advancements across our WuXiDARx™, X-LinC, and WuXiTecan-1 & WuXiTecan-2 platforms are accelerating the development of next-generation bioconjugates, positioning us at the forefront of innovation and drive value creation.
  • Recent Events – To further advance our evolving growth strategy and strengthen our next phase of expansion, we continue to scale and innovate across our payload-linkers platform.
    • Jiangyin site: we have planned a new manufacturing facility as our Jiangyin site. This strategic investment establishes scalable production capabilities for emerging novel payload-linkers, including dual-payloads, AOC, and as well as the PPQ batches supply for late-stage projects. 5x the volume of payload-linker production compared to current level at Wuxi site
    • Technology platform-driven value creation: We have invested consistently in R&D innovation to unlock potential value. In February, we entered into a new flagship strategic collaboration with Earendil Labs, to out-licensing our proprietary WuXiTecan-2, with total potential consideration of up to US$885 million, including upfront, milestone and royalty payments.

Financial Highlights for Annual Results of 2025

Revenue

The Group’s revenue increased by 46.7% YoY to RMB 5,944 million for the year ended December 31, 2025. This increase was primarily attributable to (i) the growth in the number of customers and projects, driven by continued active development of the global ADC and broader bioconjugates market, (ii) the increasing market share through the Group’s established position as a leading ADC CRDMO service provider in that market, and (iii) the steady advancement of the Group’s projects into later stages.

Gross Profit and Its Margin

The Group’s gross profit increased by 72.5% YoY to RMB 2,139 million, with a gross profit margin of  36.0% for the year ended December 31, 2025, and a 5.4 percentage points increase compared to that of 2024. This improvement is driven by (i) the enhanced overall operation and manufacturing efficiency, (ii) the utilization ratio of production facilities continued to improve, mainly due to strong customer demand, and (iii) the successful ramp-up of operating production lines including BCM2 L2 and DP3.

Adjusted Net Profit and Its Margin

The Group’s adjusted net profit increased by 69.9% YoY to RMB 1,559 million, demonstrating the strong profit growth momentum of the Group’s core operating business. The margin of adjusted net profit was 26.2% for the year ended December 31, 2025, and a 3.6 percentage points increase compared to that of 2024.

Customers and Projects Highlights for Annual Results of 2025

  • We have continuously expanded our customer base, reaching a cumulative total of 643, through strong customer-enabling empowerment.
  • The “Enable, Follow, and Win the Molecule” strategy continued to drive sustained and rapid project growth. The total number of integrated projects (“iCMC projects”) is 252, with a record 70 newly signed integrated projects.
  • The Group has successfully secured over 18 PPQ projects, with 10 new PPQ projects added in 2025.
  • The Group has a diversified project base covering both innovative ADC and broader bioconjugate (“XDC”) projects. The total number of integrated ADC projects reached 226, and the number of integrated XDC projects increased to 26.
  • In 2025, the Group explored over 5,600 molecules of multiple modalities, including bispecific ADCs, dual-payload ADCs, degrader-antibody conjugates (DAC), antibody-oligonucleotide conjugates (AOC), antibody-peptide conjugates (APC), lysosome-targeting chimaeras (LYTAC), etc.

Fully Integrated R&D Technology Platform for Annual Results of 2025

The Group strives to empower customers with cutting-edge conjugation and payload-linker technologies, along with extensive expertise in bioconjugate development capabilities to fulfill diverse R&D requirements.

WuXiDARx™

  • The proprietary WuXiDARx™ technology aims to meet customers’ demands for highly homogeneous ADCs with a wide range of DAR values at clinically validated conjugation sites.
  • WuXiDARx™ technology enables dual-payload ADC generation via native interchain cysteine sites without antibody engineering or enzymatic conjugation, offering a streamlined, cost-effective single-platform solution.
  • The platform has successfully facilitated customers to bring 8 ADC pipelines from preclinical stage to clinical stage.
  • WuXiDAR2™ offers narrow DAR distribution with a simple process; WuXiDAR1™ combines the process of WuXiDAR2™ with thiol-rebridging connector to produce homogeneous DAR1 which could be potentially developed in AOCs/APCs.

X-LinC

  • The proprietary X-LinC technology could potentially enhancing ADC stability and therapeutic window since the data demonstrated that it significantly improves plasma stability by replacing the maleimide connector.

WuXiTecan

  • The Group is developing its proprietary payload and hydrophilic linker to enable ADCs with better stability, hydrophilicity, and tolerability.
  • The newly launched WuXiTecan-1 and WuXiTecan-2 platforms have demonstrated excellent efficacy and safety profiles in preclinical studies. Notably, WuXiTecan-2 based dual-payload (MMAE+WuXiTecan-2) ADC achieved enhanced anti-tumor efficacy in CDX model.
  • Customers are actively evaluating the performance of WuXiTecan‑1 and WuXiTecan‑2, with potential collaborations under discussion involving our proprietary payloads featuring novel mechanisms of action and multi‑payload platform.

Capacity Expansion & Business Operation Updates for Annual Results of 2025

  • The total number of full-time employees increased to 2,662 in the Group, driven by rapid business growth and the Group’s capacity expansion.
  • All the Group’s manufacturing operations are conducted in accordance with the GMP regulations set by the FDA, EMA, and NMPA. The Group has completed over 200 GMP audits from global customers, including 20 audits by EU Qualified Persons.
    • Wuxi site: Further increased its integrated manufacturing capacities. The DP5 and DP6 facility in Wuxi is currently under construction.
    • Singapore site: On track to begin GMP release in 2026 1H, driven by solid overseas customer demand. This state-of-the-art site expands our global manufacturing footprint and reinforces our “China + Singapore” dual sourcing strategy, delivering enhanced supply security and operational agility for customers worldwide.
    • Shanghai site: Further investments in the discovery and technology frontier as global R&D center.
  • Executed two strategic acquisitions aligned with core growth objectives, significantly strengthening manufacturing and R&D capabilities:
    • Suzhou site: the acquisition of BioDlink further enhances our integrated bioconjugate production covering mAb, DS and DP, and expands our customer base and project pipelines.
    • Hefei site: the acquisition expands our expertise in peptide and oligonucleotide synthesis, enabling accelerated development of novel conjugates.
  • The Group was named the winner of “Best CDMO” for the third consecutive year in 2023, 2024 and 2025, as well as “Best CRO” at the 2025 World ADC Awards.
  • The Group also received multiple awards from the 2025 Extel ranking in diverse categories, signifying our commitment to high-quality corporate governance and investor interactions.
  • The Group is committed to strengthen ESG governance and received top-tier ratings in ESG rankings, reflecting our exceptional performance in corporate responsibility, risk management, and ethical business conduct.

CEO Comment

Dr. Jimmy Li, CEO of WuXi XDC, stated, “2025 was a transformative year for WuXi XDC, as we solidified our leadership in global biconjugate CRDMO market and completed several key strategic initiatives: we expanded our production capacity footprint through ‘organic expansion + strategic acquisition’ and established our Singapore site, which is expected to achieve GMP release in the first half of 2026, building a truly global supply chain system. Recently, we also entered into a technology licensing partnership for WuXiTecan-2, helping our clients accelerate bioconjugates development and realize the value resonance of our proprietary technology platforms. Looking ahead to 2026, we will continue to uphold our unwavering commitment to innovation, operational excellence, and collaboration with our clients. We will empower our customers with continuous evolution, bring breakthrough therapies to more patients worldwide, and lead the development of the industry.”

Key Financials Ratios (For the Year Ended December 31)

Key Financials (RMB Mn)

2025

2024

YoY%

Revenue

[5,944]

4,052

[46.7%]

Gross Profit 

[2,139]

1,240

[72.5%]

Margin (%)

[36.9%]

30.6 %

Adjusted Net Profit 

[1,559]

917

[69.9%]

Margin (%)

[26.2%]

22.6 %

About WuXi XDC

WuXi XDC Cayman Inc. (“WuXi XDC”, stock code: 2268.HK) is a leading global CRDMO focused on bioconjugate market. It provides end-to-end contract research, development and manufacturing services for ADC and broader bioconjugates. For more information about WuXi XDC, please visit: www.wuxixdc.com 

Contacts

Investor: wuxixdc.ir@wuxibiologics.com
Media: wuxixdc_pr@wuxibiologics.com
BD: wuxixdc_info@wuxibiologics.com

Forward-Looking Statements

This presentation may contain certain “forward-looking statements” which are not historical facts, but instead are predictions about future events based on our beliefs as well as assumptions made by and information currently available to our management. Although we believe that our predictions are reasonable, future events are inherently uncertain, and our forward-looking statements may turn out to be incorrect. Our forward-looking statements are subject to risks relating to, among other things, the ability of our service offerings to compete effectively, our ability to meet timelines for the expansion of our service offerings, and our ability to protect our customers’ intellectual property. Our forward-looking statements in this presentation speak only as of the date on which they are made, and we assume no obligation to update any forward-looking statements except as required by applicable law or listing rules. Accordingly, you are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. All forward-looking statements contained herein are qualified by reference to the cautionary statements set forth in this section.

Use of Adjusted Financial Measures (Non-IFRS Measures)

The Group defines “adjusted net profit attributable to owners of the Company” as net profit attributable to owners of the Company after elimination of share-based compensation expense as non-cash expenditure, net foreign exchange loss or gain as non-operating item, non-recurring/one-off transaction costs as non-operating item, and net of interest income and finance costs as non-operating item. We believe that the adjusted financial measures used in this presentation are useful for understanding and assessing underlying business performance and operating trends, and we believe that management and investors may benefit from referring to these adjusted financial measures in assessing our financial performance by eliminating the impact of certain unusual and non-recurring items that we do not consider indicative of the performance of our business. However, the presentation of these non-IFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with IFRS. You should not view adjusted results on a stand-alone basis or as a substitute for results under IFRS, or as being comparable to results reported or forecasted by other companies.

 

Hotel Linen Manufacturer HANBI Optimizes Hotel ROI with 30% More Durable, High-Hygiene Bedding

By
Advertorial Desk
-

By integrating factory-direct manufacturing and skin-friendly safety standards, HANBI delivers high-durability hotel bedding solutions that stabilize procurement budgets for 2,000+ luxury hospitality brands globally.

NANNING, CHINA, March 23, 2026 /PRNewswire/ — For decades, the global hospitality conversation has been dominated by mattress “hardware” from giants like Sealy and Simmons. But a critical shift is happening in the “software” of sleep: the hotel linens that define a guest’s direct tactile experience. HANBI, a vertically integrated hotel linen manufacturer, today announced the global expansion of its high-performance hotel bedding solutions. By addressing the industry’s chronic struggle with textile longevity, HANBI’s new line promises to extend product lifespan by 30%, offering a strategic edge to hotel owners worldwide.

HANBI delivers factory-direct bedding solutions that combine high-performance durability with the soft, tactile elegance demanded by the world's leading hospitality groups.
HANBI delivers factory-direct bedding solutions that combine high-performance durability with the soft, tactile elegance demanded by the world’s leading hospitality groups.

In an era of rising inflation, HANBI is redefining hotel ROI. The company controls the entire supply chain from raw yarn to the final product. By merging large-scale R&D with a “Factory-to-Hotel” direct model, it helps global hospitality partners—including Howard Johnson and Accord Hotels—reduce procurement overhead by 5% to 10%.

Engineered for Longevity: The 30% Advantage
The primary drain on a hotel’s linen budget is the rapid deterioration caused by industrial laundering. HANBI has neutralized this via its proprietary reinforced weaving technology. This ensures that every hotel bedding set maintains its structure, whiteness, and “first-day” feel for up to 30% longer than standard industry alternatives.

“We don’t just weave fabric; we engineer performance for the modern hotel linen factory,” says a spokesperson for HANBI. “Our linens undergo rigorous pre-shrinking and high-temperature setting. This ensures that a HANBI bed sheet retains its crisp, white, ‘first-day’ aesthetic, which is essential for any hotel luxury bedding standard. For a hotel owner, that 30% extra life is pure profit.”

Professional Hygiene Standards in a Luxury Setting
Post-pandemic travelers demand more than just comfort; they demand uncompromising hygiene. HANBI’s unique advantage lies in its dual-track production: applying the same strict hygiene standards found in their hospital bed sheets to their commercial hotel towels and linens. All core products are manufactured under strict safety standards, guaranteeing they are skin-friendly and free from harmful irritants. This remains a critical benchmark for eco-conscious wholesale hotel supplies.

One-Stop Integration: From Hotel Pillows to Amenities
HANBI’s “One-Stop” philosophy simplifies the fragmented procurement process. Their integrated catalog covers every guest touchpoint:

  • Hotel Bedding & Sets: High-thread-count cotton with superior breathability and durability.
  • Hotel Towels & Bathrobes: High-GSM, long-staple cotton for maximum absorbency and softness.
  • Guest Room Accessories: From hotel pillows to ergonomic slippers and bespoke amenity kits that align with a brand’s unique DNA.

Market Validation & Global Reach
Late shipments are a constant headache for hotel managers. HANBI avoids this drama by maintaining a 98% on-time delivery rate. This consistency explains why 90% of their clients have stuck with the company for three years or more. Beyond just shipping products, HANBI acts as an agile OEM and ODM partner. This gives boutique owners and global giants the power to prototype a signature look and scale it across properties without the usual lead-time headaches or budget creep.

About HANBI
HANBI is a leading vertically integrated hotel linen manufacturer specializing in professional hospitality textiles. Unlike traditional trading companies, HANBI operates its own state-of-the-art hotel linen factory, ensuring total control over quality, cost, and lead times. From premium hotel linens to sustainable fabrics meeting the rigorous hygiene standards, HANBI is the “invisible champion” supporting the world’s most demanding hospitality brands.

For more information, please visit: https://www.hanbi-hotelsupplies.com/

Media Contact:
Company Name: Guangxi Hanbi Textile Co., Ltd.
Telephone: 0771-5585836
Email: sammi@hanbitextile.com
WhatsApp: +86 15878178593

Frost & Sullivan Warns Invasive AI Agents Could Undermine Mobile Ecosystem Trust and Global Competitiveness

By
Advertorial Desk
-

New white paper calls for dual-authorization governance framework as AI agents reshape mobile value chains

SHENZHEN, China, March 23, 2026 /PRNewswire/ — According to Frost & Sullivan’s new analysis, White Paper on the Governance of Invasive Agents 2026, the rapid evolution of AI agent technology from proof-of-concept to large-scale deployment is beginning to disrupt the foundational trust mechanisms of the mobile internet ecosystem.

System-Level Agents Reshape Control and Value Distribution

As AI agents increasingly become the primary interface for user interaction, traditional mobile applications risk being relegated to execution layers rather than points of engagement. Activities such as search, comparison, and transaction initiation are progressively shifting upstream to the agent layer – reducing direct user interaction with applications and weakening established monetization models.

Frost & Sullivan analysis suggests that if invasive agents reach a 25% user penetration rate, the commercial value of utility applications could decline by up to 39%, while content and social platforms may see reductions of approximately 19.5%, and transactional applications around 15.4%.

Rising Governance, Cost, and Security Pressures

Rather than creating significant new market value, invasive agents are expected to drive a redistribution of existing traffic and revenues – intensifying competition within the ecosystem. Application developers may be forced to respond with increased investment in security, interface adjustments, and anti-automation measures.

At the same time, the concentration of high-level system permissions within a single agent environment amplifies systemic risk. Potential vulnerabilities – including prompt injection attacks and unintended automated actions – could result in privacy breaches, financial loss, and broader ecosystem instability.

Frost & Sullivan estimates that at a 25% penetration level, mobile application development costs could increase by approximately 16%, while overall ecosystem governance costs may rise by more than 34%.

Call for a Trusted Governance Framework

To ensure sustainable growth, Frost & Sullivan emphasizes the need for a governance model built on dual authorization and full-chain auditability. Under this framework, AI agents must obtain not only user consent for system-level permissions but also explicit authorization from application providers for executing underlying business actions.

AI agents represent a significant step forward in digital interaction models, but their long-term success depends on trust, transparency, and accountability. A governance framework grounded in dual authorization and auditability will be critical to balancing innovation with ecosystem stability and user protection.

Trust as a Prerequisite for Global AI Competitiveness

Frost & Sullivan notes that global competition in AI is no longer defined solely by technological capability or deployment speed. Governance capacity, trust infrastructure, and alignment with international standards are emerging as critical differentiators.

For China’s AI industry, the report highlights that pursuing rapid expansion at the expense of trust could limit international collaboration opportunities and undermine long-term global credibility. Conversely, a governance approach rooted in security, interoperability, and accountability will be essential to sustaining global competitiveness.

To access the full White Paper on the Governance of Invasive Agents 2026 and explore how organizations can navigate the evolving AI agent landscape, click here.

About Frost & Sullivan

Frost & Sullivan, the Growth Pipeline Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation, and leadership. The company’s Growth Pipeline as a Service provides the CEO’s Growth Team with transformational strategies and best-practice models to drive the generation, evaluation, and implementation of powerful growth opportunities. For over 60 years, Frost & Sullivan has partnered with investors, corporate leaders, and governments to identify, prioritize, and execute transformational growth strategies.

Your Transformational Growth Journey Starts Here: Schedule Your Growth Pipeline Dialog™ with the Frost & Sullivan team.

Contact:
Rachel Zhang
Frost & Sullivan China
E: rachel.zhang@frostchina.com
T: +86 021-3209-6800

Olight and Tesla Owners of Silicon Valley Spotlight the ArkPro for Spring Break Travel Safety

By
Advertorial Desk
-

SHENZHEN, China, March 23, 2026 /PRNewswire/ — As Spring Break travel surges across the United States, more drivers are preparing for longer road trips, remote stops, and unpredictable situations on the road. From nighttime charging to roadside emergencies, travel today requires a new level of readiness—especially after dark.

To explore these real-world scenarios, Olight has partnered with Tesla Owners of Silicon Valley to highlight how compact, versatile, and high-performance lighting tools like the ArkPro are becoming essential for modern travel safety.

Olight x Tesla Owners of Silicon Valley
Olight x Tesla Owners of Silicon Valley

A New Essential for Modern Travel

The ArkPro is designed not just as a flashlight, but as a compact safety and readiness tool for travelers. With four integrated light sources and seven lighting modes, a magnetic hands-free design, and a portable form factor, it supports a wide range of real-world scenarios, from roadside inspections to campsite setup, where reliable visibility is essential.

Insights from Evolving Travel Habits

Insights from the Tesla owner community reinforce a broader trend: drivers are placing greater importance on preparedness as travel becomes more flexible and unpredictable. From late-night stops to unfamiliar surroundings, dependable lighting is increasingly viewed as a necessity rather than an accessory.

The Tesla Owners of Silicon Valley vice president shared how the ArkPro Ultra has already become part of his routine: “My wife and I walk every night, and having a reliable flashlight is a must—whether spotting wildlife or crossing dark streets where drivers aren’t always paying attention. The ArkPro Ultra’s bright beam and compact design have replaced our bulkier flashlight entirely.”

His experience highlights how versatile lighting tools are evolving from optional gear into everyday essentials—whether for neighborhood walks or Spring Break road trips.

From Convenience to Preparedness

Lighting tools are no longer viewed as optional accessories, but as essential components of everyday preparedness. Whether during a planned road trip or an unexpected stop, reliable visibility can directly impact safety and decision-making. The ArkPro reflects this shift—bridging everyday carry with travel readiness and delivering dependable illumination when it matters most.

To mark the season, Olight is launching a limited-time Spring Break campaign to engage its community and highlight evolving travel needs. For more product information, please visit the official website.

About Olight

Founded in 2007, Olight is a global innovator in portable lighting, offering high-tech solutions for everyday carry, outdoor, tactical, and professional use. With over 1,200 product patents and international recognitions, including the prestigious iF Design Award and Red Dot Design Award, Olight reaches users in over 100 countries worldwide.

 

Alibaba International Launches Accio Work, an Enterprise AI Agent for Global Businesses

By
Advertorial Desk
-

Accelerating Agentic Business: A proactive enterprise-grade AI Agent team built for secure global operations

NEW YORK, March 23, 2026 /PRNewswire/ — Alibaba International unveiled Accio Work, a plug-and-play enterprise AI agent that equips businesses with an immediate, no-code taskforce. Requiring zero setup, the platform deploys specialized agents to execute complex, long-horizon operations from day one, signaling a significant shift toward “Agentic Business”—a new era where AI moves beyond passive Q&A tools to become active, autonomous executors.

First introduced in November 2024 as an AI-powered B2B sourcing engine, Accio has since rapidly evolved into a full-scale AI agent, now serving over 10 million monthly active users globally. The launch of Accio Work marks a new phase in this evolution—moving beyond sourcing to a full-scale enterprise AI agent designed to support the diverse operational needs of SMEs worldwide.

“Our vision is to democratize enterprise-grade AI,” said Kuo Zhang, President of Alibaba.com and VP of Alibaba International. “We want every entrepreneur—regardless of team size—to access an intelligent workforce that operates with the scale of a major corporation. Small businesses will find Accio Work especially useful.”

A Proactive, Ready-to-Use “Agent Team”

For non-technical entrepreneurs, building a custom AI workforce usually means navigating complex engineering and risky deployments. Accio Work removes these barriers with a pre-configured team of agents designed for the entire SME lifecycle—from initial market analysis, design, and sourcing to long-term store optimization and inventory monitoring.

Its secret lies in dynamic orchestration: upon receiving a goal, the system instantly assembles a cross-functional “squad” of specialized agents – analysts, creators, logistics experts – to work in parallel.

Beyond handling long-term operations, the agent team proactively provides strategic insights and suggestions. This enables SMEs and solo founders to run end-to-end global commerce workflows with enterprise-grade precision, requiring no code or setup.

Autonomous Execution and Global Connectivity

Accio Work enables entrepreneurs to run online businesses or physical stores with a new level of automation, specifically designed to alleviate the heavy operational burden faced by SMEs. Users can deploy a customizable fleet of AI agents to handle critical tasks, including:

  • Automated Compliance: Managing real-time VAT filings, tax refunds, and customs documentation across more than 100 markets.
  • Autonomous Sourcing: Executing Request for Quotations (RFQs) and conducting multi-round negotiations with suppliers to secure optimal terms.
  • Operational Integration: Driving marketing automation and overseeing logistics through tools like Telegram and WhatsApp.

Additionally, Accio Work allows users to encapsulate their unique processes into reusable “skills,” enabling them to standardize, share, or even monetize their expertise.

Alibaba Ecosystem-Driven Reliability and Security

Built on Alibaba Group’s proprietary ecosystem, Accio Work is structurally engineered to minimize AI hallucinations. Unlike models reliant on general knowledge prone to inaccuracies, Accio Work draws directly from real-time consumer trends and actual business transaction records across Alibaba’s e-commerce platforms. This foundation ensures every output is specific, accurate, and commercially relevant.

Recognizing the sensitivity of delegating critical tasks to AI, Accio Work employs a security-first approach featuring sandboxed environments and granular permission management. High stakes actions involving finances or file access require explicit user approval, ensuring the AI operates strictly within defined boundaries. Furthermore, the system respects data sovereignty, allowing users to choose not to save any data on servers.

Accio Work will be available on www.Accio.com by the end of March.

About Alibaba International

Alibaba International Digital Commerce Group (Alibaba International) is dedicated to supporting the development of global digital trade with AI-powered technology. It operates various platforms with distinctive business models, covering multiple countries and regions around the world.

Bybit Elevates USDC Trading With Competitive Fee Framework and Liquidity Enhancements

By
Advertorial Desk
-

DUBAI, UAE, March 23, 2026 /PRNewswire/ — Bybit, the world’s second-largest cryptocurrency exchange by trading volume, is pleased to announce enhancements to its USDC trading ecosystem, significantly lowering the barrier to trading with USDC and improving market efficiency on Bybit. The updates introduce an optimized fee structure and liquidity mechanism improvements for USDC spot and futures trading pairs for eligible Bybit traders, building on Bybit’s February 2026 deployment of dedicated USDC Futures Fee Group infrastructure.

Bybit Elevates USDC Trading With Competitive Fee Framework and Liquidity Enhancements
Bybit Elevates USDC Trading With Competitive Fee Framework and Liquidity Enhancements

Effective March 23, 2026, the enhancement applies to USDC-denominated spot and futures pairs on Bybit . Pro user fee structures and non-USDC pairs remain unchanged.

Trading With USDC: What’s Changing on Bybit

Eligible Bybit VIP users engaging in manual trading receive up to 50% taker fee reduction on USDC-denominated spot and futures pairs:

  • Spot Fee Adjustment: Taker fee across all VIP tiers will be slashed by half, with rates for Supreme VIPs at as low as 0.0225%.
  • Futures Fee Adjustment: Bybit VIPs pay half for eligible Futures trading pairs, with Supreme VIP rates at 0.015%.

In addition to the new VIP benefits, trading with USDC on Bybit is intuitive, rewarding, and transparent. Under a unified grouping framework on Bybit, all USDC perpetual and futures contracts on Bybit operate within a dedicated USDC Group, enabling streamlined risk management and coordinated development across the full suite of USDC trading pairs.

To provide better visibility into USDC markets liquidity on Bybit, the exchange has also adjusted the weighting factor for the USDC group from 5x to 8x for Market Maker performance assessment.

Leading stablecoins such as USDC have become essential infrastructure in digital finance, and Bybit’s fee reductions and liquidity improvements reflect this shift.

Terms and conditions apply. Eligibility varies by region and transaction type. For details of participation requirements and implementation timetables, users may visit: Fee discounts for retail clients on USDC trading pairs and USDC group weighting enhancements

Users may review their current Market Maker level, Pro fee structure, and performance metrics on the Bybit official website.

#Bybit / #TheCryptoArk / #IMakeIt

About Bybit

Bybit is the world’s second-largest cryptocurrency exchange by trading volume, serving a global community of over 80 million users. Founded in 2018, Bybit is redefining openness in the decentralized world by creating a simpler, open and equal ecosystem for everyone. With a strong focus on Web3, Bybit partners strategically with leading blockchain protocols to provide robust infrastructure and drive on-chain innovation. Renowned for its secure custody, diverse marketplaces, intuitive user experience, and advanced blockchain tools, Bybit bridges the gap between TradFi and DeFi, empowering builders, creators, and enthusiasts to unlock the full potential of Web3. Discover the future of decentralized finance at Bybit.com.

For more details about Bybit, please visit Bybit Press
For media inquiries, please contact: media@bybit.com
For updates, please follow: Bybit’s Communities and Social Media

Discord | Facebook | Instagram | LinkedIn | Reddit | Telegram | TikTok | X | Youtube

New Cognex Research Reveals Manufacturers Increasingly Expect AI Vision Systems to Deliver Both High Performance and Simplicity

By
Advertorial Desk
-

Global study of 500+ manufacturers shows shifting priorities, rapid deployment, and new expectations for next generation machine vision systems

NATICK, Mass., March 23, 2026 /PRNewswire/ — Cognex Corporation (NASDAQ: CGNX), the global leader in industrial machine vision, today announced the release of How AI Is Transforming Machine Vision Through Performance and Simplicity. The new report draws on firsthand insights from over 500 manufacturers, integrators, and OEMs to explore how artificial intelligence is making production lines smarter, more accurate, and easier to run.

Cognex Research Report: How AI is Transforming Machine Vision Through Performance and Simplicity
Cognex Research Report: How AI is Transforming Machine Vision Through Performance and Simplicity

According to the report, more than half of respondents (57%) already use AI in their machine vision operations, with another 30% planning deployments in the near term. Adoption is strongest in automotive, electronics, and logistics—industries where product variability, tighter tolerances, and increasing automation are pushing vision systems to new levels of capability.

“This research confirms what we see globally: AI isn’t just improving machine vision performance—it’s reshaping how manufacturers think about quality, efficiency, and automation,” said Cognex President and CEO Matt Moschner. “The convergence of powerful AI and practical usability enables factories to deploy intelligence at the edge, adapt in real time, and accelerate toward fully autonomous operations.”

Accuracy Drives Adoption, but Usability Defines Long-Term Value
While improved accuracy is the primary driver for initial adoption, particularly AI’s strength in detecting subtle and complex defects, the study shows that usability becomes increasingly critical over time, which could potentially be due to product advancements.

Respondents with more than three years of AI vision experience were significantly more likely to report that AI systems are:

  • Easy to scale across multiple sites: +10.9 points (86.1% vs. 75.3%)
  • Fast to develop and deploy: +9.1 points (81.2% vs. 72.1%)

“Newer AI vision solutions include features such as intuitive visualization tools, robust audit trails, reduced data requirements, and lower dependence on specialized expertise,” said Shirin Saleem, VP of Engineering, Cognex. “These advancements have significantly narrowed the gap between perceived implementation risk and real-world user experience.”

About the Research
The research is based on a survey of 500+ manufacturers, OEMs, and system integrators in North America, Europe, and Asia, covering a range of industries including automotive, electronics, FMCG, healthcare, and logistics. Respondents ranged from mid-sized to global enterprises and shared real-world experiences with AI-based machine vision deployment, operation, and scaling. The research also explores industry‑specific adoption trends, regional differences, and key considerations for organizations evaluating AI‑driven vision systems. The full report, How AI Is Transforming Machine Vision Through Performance and Simplicity, is available for download here.

About Cognex Corporation
For over 40 years, Cognex has been making advanced machine vision easy, paving the way for manufacturing and distribution companies to become faster, smarter, and more efficient through automation. Innovative technology in our vision sensors and systems solves critical manufacturing and distribution challenges, providing unparalleled performance for industries from automotive to consumer electronics to packaged goods.

Cognex makes these tools more capable and easier to deploy thanks to a longstanding focus on AI, helping factories and warehouses improve quality and maximize efficiency without needing highly technical expertise. We are headquartered near Boston, USA, with locations in over 30 countries and more than 30,000 customers worldwide. Learn more at cognex.com.

Media Contact:
Liz Bradley – Head of Communications
Cognex Corporation
pr@cognex.com

IR Contact:
Greer Aviv – Head of Investor Relations
Cognex Corporation
ir@cognex.com

 

1...797798799...6,561Page 798 of 6,561